medgenМедицинская генетикаMedical Genetics2073-7998Publishing House «Genius Media» LLC10.25557/2073-7998.2024.07.3-14medgen-2504Research ArticleНАУЧНЫЙ ОБЗОРREVIEWНаследственный рак предстательной железыHereditary prostate cancerМихайленкоД. С.MikhaylenkoD. S.

Михайленко Дмитрий Сергеевич

115522, г. Москва, ул. Москворечье, д. 1

119048, г. Москва, ул. Трубецкая, д. 8/2

Dmitry S. Mikhaylenko

1 Moskvorechie st., Moscow, 115522

8/2 Trubetskaya st., Moscow, 119048

dimserg@mail.ruЗалетаевД. В.ZaletayevD. V.

115522, г. Москва, ул. Москворечье, д. 1

1 Moskvorechie st., Moscow, 115522

ФГБНУ Медико-генетический научный центр имени академика Н.П. Бочкова; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияResearch Centre for Medical Genetics; I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБНУ Медико-генетический научный центр имени академика Н.П. БочковаРоссияResearch Centre for Medical GeneticsRussian Federation202410102024237314Copyright © Михайленко Д.С., Залетаев Д.В., 20242024Михайленко Д.С., Залетаев Д.В.Mikhaylenko D.S., Zaletayev D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medgen-journal.ru/jour/article/view/2504

Рак предстательной железы (РПЖ) относят к частым онкоурологическим заболеваниям у мужчин. Часть случаев РПЖ можно рассматривать как клинические проявления наследственных онкологических синдромов – заболеваний, обусловленных герминальными мутациями и характеризующихся повышенным риском развития определенных типов опухолей. Риск РПЖ повышен при герминальных мутациях в генах BRCA1/2 и других генах системы репарации путем гомологичной рекомбинации, синдромах Линча, Ли-Фраумени и ряде других заболеваний. В настоящем обзоре систематизированы клинико-генетическая характеристика, методы диагностики, схемы динамического наблюдения  носителей герминальных мутаций и показания к назначению таргетной терапии при наследственном РПЖ. Обзор ориентирован на генетиков, онкологов и врачей смежных специальностей.

Prostate cancer (PCa) is one of the most common oncological diseases in men. Some cases of PCa can be considered as clinical manifestations of hereditary cancer syndromes – diseases caused by germline mutations and characterized by an increased risk of developing certain types of tumors. The risk of PCa is increased in individuals with germline mutations in the BRCA1/2 genes and other homologous recombination repair genes (HRR), Lynch syndrome, Li-Fraumeni syndrome and a number of other hereditary diseases. We have described clinical and genetic characteristics, diagnostic methods, management and genetic counseling of patients with hereditary forms of PCa, as well as indications for targeted therapy. This review is aimed at clinical and laboratory geneticists, oncologists and related specialists.

рак предстательной железынаследственный онкологический синдроммутациясеквенированиединамическое наблюдениеprostate cancerhereditary cancer syndromemutationsequencingactive monitoring of mutation carriersРабота выполнена в рамках государственного задания Минобрнауки России для ФГБНУ «МГНЦ» на 2024 гThe study was carried out according to the state assignment of the Ministry of Science and Higher Education of the Russian Federation for the Research Centre for Medical Genetics.ReferencesСостояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.Sostoyaniye onkologicheskoy pomoshchi naseleniyu Rossii v 2022 godu. Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhzadovoy [The cancer care in Russia in 2022. Ed. by Kaprin A.D., Starinskiy V.V., Shahzadova A.O.] M.: PA Hertzen Moscow Research Oncological Institute branch of the NMRC of radiology at Ministry of Health of Russian Federation, 2022. 239 pp. (In Russ.)Шикеева А.А., Исаева Н.И., Васильева Е.Н. и др. Наследственные онкологические синдромы: клинические и генетические аспекты, диагностика. – М.: Лайвбук, 2022. 108 с.Shikeeva AA, Isaeva NI, Vasilyeva EN, et al. Nasledstvennyye onkologicheskiye sindromy: klinicheskiye i geneticheskiye aspekty, diagnostika [Hereditary tumor syndromes: clinical and genetic aspects, diagnostics]. M.: Layvbuk [M.: Livebook], 2022. 108 pp. (In Russ.)Сheng H.H., Sokolova A.O., Gulati R., et al. Internet-based germline genetic testing for men with metastatic prostate cancer. JCO Precis Oncol. 2023;7:e2200104. doi:10.1200/PO.22.00104.Сheng H.H., Sokolova A.O., Gulati R., et al. Internet-based germline genetic testing for men with metastatic prostate cancer. JCO Precis Oncol. 2023;7:e2200104. doi:10.1200/PO.22.00104.Vlaming M., Ausems M.G.E.M., Schijven G., et al. Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives. Fam Cancer. 2024;23(2):165-175. doi: 10.1007/s10689-024-00377-0.Vlaming M., Ausems M.G.E.M., Schijven G., et al. Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives. Fam Cancer. 2024;23(2):165-175. doi: 10.1007/s10689-024-00377-0.Pritchard C.C., Mateo J., Walsh M.F., et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-53. doi: 10.1056/NEJMoa1603144.Pritchard C.C., Mateo J., Walsh M.F., et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-53. doi: 10.1056/NEJMoa1603144.Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39:79-86. doi: 10.1200/EDBK_238977.ilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39:79-86. doi: 10.1200/EDBK_238977.Beebe-Dimmer J.L., Kapron A.L., Fraser A.M., et al. Risk of prostate cancer associated with familial and hereditary cancer syndromes. J Clin Oncol. 2020;38(16):1807-1813. doi: 10.1200/JCO.19.02808.Beebe-Dimmer J.L., Kapron A.L., Fraser A.M., et al. Risk of prostate cancer associated with familial and hereditary cancer syndromes. J Clin Oncol. 2020;38(16):1807-1813. doi: 10.1200/JCO.19.02808.D’Elia G., Caliendo G., Tzioni M.M., et al. Increased risk of hereditary prostate cancer in Italian families with hereditary breast and ovarian cancer syndrome harboring mutations in BRCA and in other susceptibility genes. Genes (Basel). 2022;13(10):1692. doi: 10.3390/genes13101692.D’Elia G., Caliendo G., Tzioni M.M., et al. Increased risk of hereditary prostate cancer in Italian families with hereditary breast and ovarian cancer syndrome harboring mutations in BRCA and in other susceptibility genes. Genes (Basel). 2022;13(10):1692. doi: 10.3390/genes13101692.Ni Raghallaigh H., Eeles R. Genetic predisposition to prostate cancer: an update. Fam Cancer. 2022;21(1):101-114. doi: 10.1007/s10689021-00227-3.Ni Raghallaigh H., Eeles R. Genetic predisposition to prostate cancer: an update. Fam Cancer. 2022;21(1):101-114. doi: 10.1007/s10689021-00227-3.Olmos D., Lorente D., Alameda D., et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35(5):458-472. doi: 10.1016/j.annonc.2024.01.011.Olmos D., Lorente D., Alameda D., et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35(5):458-472. doi: 10.1016/j.annonc.2024.01.011.Yang X., Leslie G., Doroszuk A., et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674-685. doi: 10.1200/JCO.19.01907.Yang X., Leslie G., Doroszuk A., et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674-685. doi: 10.1200/JCO.19.01907.Wokołorczyk D., Kluźniak W., Stempa K., et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125(4):569575. doi: 10.1038/s41416-021-01410-0.Wokołorczyk D., Kluźniak W., Stempa K., et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125(4):569575. doi: 10.1038/s41416-021-01410-0.Stempa K., Wokołorczyk D., Kluźniak W., et al. Do BARD1 mutations confer an elevated risk of prostate cancer? Cancers (Basel). 2021;13(21):5464. doi: 10.3390/cancers13215464.Stempa K., Wokołorczyk D., Kluźniak W., et al. Do BARD1 mutations confer an elevated risk of prostate cancer? Cancers (Basel). 2021;13(21):5464. doi: 10.3390/cancers13215464.Vietri M.T., D’Elia G., Caliendo G., et al. Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci. 2021;22(7):3753. doi: 10.3390/ijms22073753.Vietri M.T., D’Elia G., Caliendo G., et al. Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci. 2021;22(7):3753. doi: 10.3390/ijms22073753.Шегай П.В., Шаталов П.А., Шинкаркина А.П. и др. Под ред. акад. РАН А.Д. Каприна. Молекулярно-генетические исследования в онкологии. Учебно-методическое пособие. Обнинск: 2023. ФГБУ «НМИЦ радиологии» Минздрава России. – 82 с.Shegay P.V., Shatalov P.A., Shinkarkina A.P. et al. Ed. by Kaprin A.D. Molekulyarno-geneticheskiye issledovaniya v onkologii. Uchebno-metodicheskoye posobiye [Molecular genetic tests in oncology]. Obninsk: 2023. National Medical Research Center of Radiology, Ministry of Health. 82 pp. (In Russ.).Brandao A., Paulo P., Maia S., et al. The CHEK2 variant c.349A>G is associated with prostate cancer risk and carriers share a common ancestor. Cancers (Basel). 2020;12(11):3254. doi: 10.3390/cancers12113254.Brandao A., Paulo P., Maia S., et al. The CHEK2 variant c.349A>G is associated with prostate cancer risk and carriers share a common ancestor. Cancers (Basel). 2020;12(11):3254. doi: 10.3390/cancers12113254.Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):40524. doi: 10.1038/gim.2015.30.Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):40524. doi: 10.1038/gim.2015.30.Рыжкова О.П., Кардымон О.Л., Прохорчук Е.Б. и др. Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS) (редакция 2018, версия 2). Медицинская генетика 2019; 18(2): 3-23. doi: 10.25557/2073-7998.2019.02.3-23.Ryzhkova O.P., Kardymon O.L., Prohorchuk E.B., et al. Rukovodstvo po interpretatsii dannykh posledovatel’nosti DNK cheloveka, poluchennykh metodami massovogo parallel’nogo sekvenirovaniya (MPS) (redaktsiya 2018, versiya 2) [Guidelines for the interpretation of massive parallel sequencing variants (update 2018, v2)]. Meditsinskaya genetika [Medical Genetics]. 2019;18(2):3-23. (In Russ.) https://doi.org/10.25557/2073-7998.2019.02.3-23Garrett A., Durkie M., Callaway A., et al. Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations. J Med Genet. 2021;58(5):297304. doi: 10.1136/jmedgenet-2020-107248.Garrett A., Durkie M., Callaway A., et al. Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations. J Med Genet. 2021;58(5):297304. doi: 10.1136/jmedgenet-2020-107248.CanVIG-UK specific recommendations on individual genes involved in carcinogenesis [https://www.cangene-canvaruk.org/gene-specific-recommendations] (accessed 09.06.2024)CanVIG-UK specific recommendations on individual genes involved in carcinogenesis [https://www.cangene-canvaruk.org/gene-specific-recommendations] (accessed 09.06.2024)Hanson H., Astiazaran-Symonds E., Amendola L.M., et al. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(10):100870. doi: 10.1016/j.gim.2023.100870.Hanson H., Astiazaran-Symonds E., Amendola L.M., et al. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(10):100870. doi: 10.1016/j.gim.2023.100870.Bhattacharya P., McHugh T.W. Lynch Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jan.Bhattacharya P., McHugh T.W. Lynch Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jan.Цуканов А.С., Кашников В.Н., Пикунов Д.Ю., Чернышов С.В. Синдром Линча. Диагностика, мониторинг и лечение. Учебно-методическое пособие. М.: Изд-во Боргес. 2021. 40 с.Tsukanov A.S., Kashnikov V.N., Pikunov D.Y., Chernyshov S.V. Sindrom Lincha. Diagnostika, monitoring i lecheniye. Uchebno-metodicheskoye posobiye [Lynch syndrome: diagnostics, management and treatment]. Moscow: Borges Publishing. 2021. 40 pp. (In Russ.).Цуканов А.С., Демидова И.А., Цаур Г.А. и др. Диагностика синдрома Линча у онкологических пациентов: позиция Межрегиональной организации молекулярных генетиков в онкологии и онкогематологии. Вопросы онкологии. 2023;69(1):7–14. doi:10.37469/0507-3758-2023-69-1-7-14.Tsukanov A.S., Demidova I.A., Tsaur G.A. et al. Diagnostika sindroma Lincha u onkologicheskikh patsiyentov: pozitsiya Mezhregional’noy organizatsii molekulyarnykh genetikov v onkologii i onkogematologii [Diagnosis of Lynch syndrome in cancer patients: the position of the Interregional Organization of Molecular Geneticists in Oncology and Oncohematology]. Voprosy Onkologii [Issues of oncology]. 2023;69(1):7-14. doi: 10.37469/0507-3758-2023-69-1-7-14. (In Russ.).Pritzlaff M., Tian Y., Reineke P., et al. Diagnosing hereditary cancer predisposition in men with prostate cancer. Genet Med. 2020;22(9):1517-1523. doi: 10.1038/s41436-020-0830-5.Pritzlaff M., Tian Y., Reineke P., et al. Diagnosing hereditary cancer predisposition in men with prostate cancer. Genet Med. 2020;22(9):1517-1523. doi: 10.1038/s41436-020-0830-5.Amadou A., Achatz M.I.W., Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30(1):23-29. doi: 10.1097/CCO.0000000000000423.Amadou A., Achatz M.I.W., Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30(1):23-29. doi: 10.1097/CCO.0000000000000423.Maxwell K.N., Cheng H.H., Powers J., et al. Inherited TP53 variants and risk of prostate cancer. Eur Urol. 2022;81(3):243-250. doi: 10.1016/j.eururo.2021.10.036.Maxwell K.N., Cheng H.H., Powers J., et al. Inherited TP53 variants and risk of prostate cancer. Eur Urol. 2022;81(3):243-250. doi: 10.1016/j.eururo.2021.10.036.Heise M., Jarzemski P., Bąk A., et al. G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men. Pol J Pathol. 2019;70(2):127-133. doi: 10.5114/pjp.2019.87103.Heise M., Jarzemski P., Bąk A., et al. G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men. Pol J Pathol. 2019;70(2):127-133. doi: 10.5114/pjp.2019.87103.Schaid D.J., McDonnell S.K., FitzGerald L.M., et al. Two-stage study of familial prostate cancer by whole-exome sequencing and custom capture identifies 10 novel genes associated with the risk of prostate cancer. Eur Urol. 2021;79(3):353-361. doi: 10.1016/j.eururo.2020.07.038.Schaid D.J., McDonnell S.K., FitzGerald L.M., et al. Two-stage study of familial prostate cancer by whole-exome sequencing and custom capture identifies 10 novel genes associated with the risk of prostate cancer. Eur Urol. 2021;79(3):353-361. doi: 10.1016/j.eururo.2020.07.038.Wokolorczyk D., Kluzniak W., Huzarski T., et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Int J Cancer. 2020;147(10):2793-2800. doi: 10.1002/ijc.33272.Wokolorczyk D., Kluzniak W., Huzarski T., et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Int J Cancer. 2020;147(10):2793-2800. doi: 10.1002/ijc.33272.Dupont W.D., Breyer J.P., Johnson S.H., et al. Prostate cancer risk variants of the HOXB genetic locus. Sci Rep. 2021;11(1):11385. doi: 10.1038/s41598-021-89399-7.Dupont W.D., Breyer J.P., Johnson S.H., et al. Prostate cancer risk variants of the HOXB genetic locus. Sci Rep. 2021;11(1):11385. doi: 10.1038/s41598-021-89399-7.Dupont W.D., Breyer J.P., Plummer W.D., et al. 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. Nat Commun. 2020 ;11(1):1523. doi: 10.1038/s41467-020-15122-1.Dupont W.D., Breyer J.P., Plummer W.D., et al. 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. Nat Commun. 2020 ;11(1):1523. doi: 10.1038/s41467-02015122-1.NCCN Guidelines. v.4.2024 Prostate Cancer. [https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf] (дата обращения 05.06.2024).NCCN Guidelines. v.4.2024 Prostate Cancer. [https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf] (accessed 05.06.2024).NCCN Guidelines. v.3.2024 Genetic / Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. [https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf] (дата обращения 05.06.2024).NCCN Guidelines. v.3.2024 Genetic / Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. [https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf] (accessed 05.06.2024).NCCN Guidelines. v.2.2023 Genetic / Familial High-Risk Assessment: Colorectal. [https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf] (дата обращения 05.06.2024).NCCN Guidelines. v.2.2023 Genetic / Familial High-Risk Assessment: Colorectal. [https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf] (accessed 05.06.2024).Макарова М.В., Немцова М.В., Черневский Д.К. и др. Медико-генетическое консультирование пациентов с выявленными клинически значимыми генетическими вариантами, ассоциированными с наследственными опухолевыми синдромами, и их родственников. Учебно-методическое пособие. М.: 2023. Издво Триумф. 71 с. ISBN 978-5-94472-150-1. doi: 10.29039/978-594472-150-1-08-2023.Makarova M.V., Nemtsova M.V., Chernevsky D.K. et al. Mediko-geneticheskoye konsul’tirovaniye patsiyentov s vyyavlennymi klinicheski znachimymi geneticheskimi variantami, assotsiirovannymi s nasledstvennymi opukholevymi sindromami, i ikh rodstvennikov. Uchebno-metodicheskoye posobiye [Medical genetic counseling of patients with identified clinically significant genetic variants associated with hereditary tumor syndromes and their relatives]. M.: 2023. Triumph Publishing House. 71 pp. (In Russ.).Хатьков И.Е., Жукова Л.Г., Данишевич А.М. и др. Рекомендации по медицинскому сопровождению пациентов с верифицированными (подтвержденными) наследственными опухолевыми синдромами и их родственников с выявленной предрасположенностью к развитию онкологических заболеваний. М.: ГБУЗ МКНЦ им. А.С. Логинова ДЗМ, 2022. -27 с.Khatkov I.E., Zhukova L.G., Danishevich A.M. et al. Rekomendatsii po meditsinskomu soprovozhdeniyu patsiyentov s verifitsirovannymi (podtverzhdennymi) nasledstvennymi opukholevymi sindromami i ikh rodstvennikov s vyyavlennoy predraspolozhennost’yu k razvitiyu onkologicheskikh zabolevaniy [Recommendations for medical counseling of patients with verified (confirmed) hereditary tumor syndromes and their relatives with an identified predisposition to the development of cancer]. M.: 2022. SBOM A.S. Loginova MCSC DMM, 27 pp. (In Russ.).Gan S., Guo Z., Zou Q., et al. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. Int Braz J Urol. 2020;46(5):786-793. doi: 10.1590/S1677-5538.IBJU.2019.0521.Gan S., Guo Z., Zou Q., et al. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. Int Braz J Urol. 2020;46(5):786-793. doi: 10.1590/S1677-5538.IBJU.2019.0521.Barber N., Ali A., editors. Urologic Cancers. Chapter 15: The role of family history and germline genetics in prostate cancer disease profile and screening (199-214 pp.). Brisbane (AU): Exon Publications; 2022. ISBN: 978-0-6453320-5-6.Barber N., Ali A., editors. Urologic Cancers. Chapter 15: The role of family history and germline genetics in prostate cancer disease profile and screening (199-214 pp.). Brisbane (AU): Exon Publications; 2022. ISBN: 978-0-6453320-5-6.Михайленко Д.С. Молекулярная генетика рака предстательной железы / Рак простаты: от протеомики и геномики к хирургии. Под ред. Коган М.И. и Пушкарь Д.Ю. РнД; Изд-во ЮНЦ РАН, 2017. 288 с.Mikhaylenko D.S. Molekulyarnaya genetika raka predstatel’noy zhelezy. V Rak prostaty: ot proteomiki i genomiki k khirurgii. Pod red. Kogan M.I. i Pushkar’ D.YU. [Molecular genetics of prostate cancer. In Prostate cancer: from proteomics and genomics to surgery. Ed. by Kogan M.I., Pushkar D.Y.]. Rostov-on-Don; South Science Center of RAS Publishing, 2017. 288 pp. (In Russ.)Horak P., Weischenfeldt J., von Amsberg G., et al. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Cold Spring Harb Mol Case Stud. 2019;5(2):a003657. doi: 10.1101/mcs.a003657. PMID: 30833416.Horak P., Weischenfeldt J., von Amsberg G., et al. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Cold Spring Harb Mol Case Stud. 2019;5(2):a003657. doi: 10.1101/mcs.a003657. PMID: 30833416.Dillon KM, Bekele RT, Sztupinszki Z, et al. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. NPJ Precis Oncol. 2022;6(1):49. doi: 10.1038/s41698-022-00291-7.Dillon KM, Bekele RT, Sztupinszki Z, et al. PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. NPJ Precis Oncol. 2022;6(1):49. doi: 10.1038/s41698-022-00291-7.Militaru F.C., Militaru V., Crisan N., et al. Molecular basis and therapeutic targets in prostate cancer: A comprehensive review. Biomol Biomed. 2023;23(5):760-771. doi: 10.17305/bb.2023.8782.Militaru F.C., Militaru V., Crisan N., et al. Molecular basis and therapeutic targets in prostate cancer: A comprehensive review. Biomol Biomed. 2023;23(5):760-771. doi: 10.17305/bb.2023.8782.Carreira S., Porta N., Arce-Gallego S., et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discov. 2021;11(11):2812-2827. doi: 10.1158/2159-8290.CD21-0007.Carreira S., Porta N., Arce-Gallego S., et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discov. 2021;11(11):2812-2827. doi: 10.1158/2159-8290. CD-21-0007.Клинические рекомендации. Рак предстательной железы. ID:12. https://roou.ru/clinical-guidelines-rpj2021/ (дата обращения 05.06.2024).Clinical Guidelines of the Russian Ministry of Health. Prostate cancer. ID:12. https://roou.ru/clinical-guidelines-rpj2021 (accessed 05.06.2024). (In Russ.)].Bugoye F.C., Torrorey-Sawe R., Biegon R., et al. Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer. Front Genet. 2023;14:1231536. doi: 10.3389/fgene.2023.1231536.Bugoye F.C., Torrorey-Sawe R., Biegon R., et al. Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer. Front Genet. 2023;14:1231536. doi: 10.3389/fgene.2023.1231536.Hougen H.Y., Graf R.P., Li G., et al. Clinical and genomic factors associated with greater tumor mutational burden in prostate cancer. Eur Urol Open Sci. 2023;55:45-49. doi: 10.1016/j.euros.2023.08.001.Hougen H.Y., Graf R.P., Li G., et al. Clinical and genomic factors associated with greater tumor mutational burden in prostate cancer. Eur Urol Open Sci. 2023;55:45-49. doi: 10.1016/j.euros.2023.08.001.Truong H., Breen K., Nandakumar S., et al. Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer. Eur Urol. 2023;83(1):29-38. doi: 10.1016/j.eururo.2022.08.028.Truong H., Breen K., Nandakumar S., et al. Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer. Eur Urol. 2023;83(1):29-38. doi: 10.1016/j.eururo.2022.08.028.Zhu J., Tucker M., Marin D., et al. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urol Oncol. 2019;37(11):813.e1-813.e9. doi: 10.1016/j.urolonc.2019.06.015.Zhu J., Tucker M., Marin D., et al. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urol Oncol. 2019;37(11):813.e1-813.e9. doi: 10.1016/j.urolonc.2019.06.015.Zurita A.J., Graf R.P., Villacampa G., et al. Genomic biomarkers and genome-wide loss-of-heterozygosity scores in metastatic prostate cancer following progression on androgen-targeting therapies. JCO Precis Oncol. 2022;6:e2200195. doi: 10.1200/PO.22.00195.Zurita A.J., Graf R.P., Villacampa G., et al. Genomic biomarkers and genome-wide loss-of-heterozygosity scores in metastatic prostate cancer following progression on androgen-targeting therapies. JCO Precis Oncol. 2022;6:e2200195. doi: 10.1200/PO.22.00195.

The authors declare that there are no conflicts of interest present.